174 related articles for article (PubMed ID: 32816945)
21. HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer.
Sonpavde G; Wang M; Peterson LE; Wang HY; Joe T; Mims MP; Kadmon D; Ittmann MM; Wheeler TM; Gee AP; Wang RF; Hayes TG
Invest New Drugs; 2014 Apr; 32(2):235-242. PubMed ID: 23609828
[TBL] [Abstract][Full Text] [Related]
22. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions.
Kageshita T; Ishihara T; Campoli M; Ferrone S
Tissue Antigens; 2005 May; 65(5):419-28. PubMed ID: 15853896
[TBL] [Abstract][Full Text] [Related]
23. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients.
Ladanyi M; Antonescu CR; Leung DH; Woodruff JM; Kawai A; Healey JH; Brennan MF; Bridge JA; Neff JR; Barr FG; Goldsmith JD; Brooks JS; Goldblum JR; Ali SZ; Shipley J; Cooper CS; Fisher C; Skytting B; Larsson O
Cancer Res; 2002 Jan; 62(1):135-40. PubMed ID: 11782370
[TBL] [Abstract][Full Text] [Related]
24. HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones.
Huarte E; Karbach J; Gnjatic S; Bender A; Jäger D; Arand M; Atanackovic D; Skipper J; Ritter G; Chen YT; Old LJ; Knuth A; Jäger E
Cancer Immun; 2004 Dec; 4():15. PubMed ID: 15600300
[TBL] [Abstract][Full Text] [Related]
25. Synovial sarcoma. A Scandinavian Sarcoma Group project.
Skytting B
Acta Orthop Scand Suppl; 2000 Apr; 291():1-28. PubMed ID: 10862210
[TBL] [Abstract][Full Text] [Related]
26. The Biology of Synovial Sarcoma: State-of-the-Art and Future Perspectives.
Fiore M; Sambri A; Spinnato P; Zucchini R; Giannini C; Caldari E; Pirini MG; De Paolis M
Curr Treat Options Oncol; 2021 Oct; 22(12):109. PubMed ID: 34687366
[TBL] [Abstract][Full Text] [Related]
27. Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG).
Moreau-Bachelard C; Campion L; Toulmonde M; Le Cesne A; Brahmi M; Italiano A; Mir O; Piperno-Neumann S; Laurence V; Firmin N; Penel N; Duffaud F; Chevreau C; Bertucci F; Narciso B; Dubray-Longeras P; Delcambre C; Saada-Bouzid E; Boudou-Rouquette P; Soulie P; Perrin C; Blay JY; Bompas E
ESMO Open; 2022 Apr; 7(2):100402. PubMed ID: 35202953
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells.
Rentzsch C; Kayser S; Stumm S; Watermann I; Walter S; Stevanoviç S; Wallwiener D; Gückel B
Clin Cancer Res; 2003 Oct; 9(12):4376-86. PubMed ID: 14555509
[TBL] [Abstract][Full Text] [Related]
29. Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy.
De Re V; Caggiari L; De Zorzi M; Talamini R; Racanelli V; D' Andrea M; Buonadonna A; Zagonel V; Cecchin E; Innocenti F; Toffoli G
PLoS One; 2014; 9(1):e84940. PubMed ID: 24497922
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors affecting survival in metastatic soft tissue sarcoma: an analysis of 110 patients.
Iqbal N; Shukla NK; Deo SV; Agarwala S; Sharma DN; Sharma MC; Bakhshi S
Clin Transl Oncol; 2016 Mar; 18(3):310-6. PubMed ID: 26243399
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series.
Yoo KH; Kim HS; Lee SJ; Park SH; Kim SJ; Kim SH; La Choi Y; Shin KH; Cho YJ; Lee J; Rha SY
BMC Cancer; 2015 Mar; 15():154. PubMed ID: 25885855
[TBL] [Abstract][Full Text] [Related]
32. NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer.
Szender JB; Papanicolau-Sengos A; Eng KH; Miliotto AJ; Lugade AA; Gnjatic S; Matsuzaki J; Morrison CD; Odunsi K
Gynecol Oncol; 2017 Jun; 145(3):420-425. PubMed ID: 28392127
[TBL] [Abstract][Full Text] [Related]
33. Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells.
Weide B; Martens A; Zelba H; Stutz C; Derhovanessian E; Di Giacomo AM; Maio M; Sucker A; Schilling B; Schadendorf D; Büttner P; Garbe C; Pawelec G
Clin Cancer Res; 2014 Mar; 20(6):1601-9. PubMed ID: 24323899
[TBL] [Abstract][Full Text] [Related]
34. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
Nakamura T; Matsumine A; Kawai A; Araki N; Goto T; Yonemoto T; Sugiura H; Nishida Y; Hiraga H; Honoki K; Yasuda T; Boku S; Sudo A; Ueda T
Cancer; 2016 May; 122(9):1408-16. PubMed ID: 26970174
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors and treatment of patients with advanced synovial sarcoma: A single-center experience.
Ates O; Aksoy S; Yeter H; Sunar V; Kertmen N; Dizdar O; Turker A; Kars A
Indian J Cancer; 2017; 54(1):321-325. PubMed ID: 29199714
[TBL] [Abstract][Full Text] [Related]
36. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
[TBL] [Abstract][Full Text] [Related]
37. Clinical and pathological features of patients with resected synovial sarcoma: a multicenter retrospective analysis of the Anatolian Society of Medical Oncology.
Tarkan Y; Erkan A; Selcuk ES; Mehmet K; Tugba KF; Ozlem US; Suleyman A; Tulay A; Bilge A; Ramazan Y; Yusuf G; Mevlude I; Umut D; Ilhan O; Abdurrahman I; Alper S; Dogan U; Necati A; Berna O; Gok DA; Ugur Y; Mahmut G
J Cancer Res Ther; 2014; 10(1):73-8. PubMed ID: 24762490
[TBL] [Abstract][Full Text] [Related]
38. Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma.
Cai W; Zhang J; Chen Y; Kong W; Huang Y; Huang J; Zhou L
Chin J Cancer; 2017 May; 36(1):47. PubMed ID: 28521783
[TBL] [Abstract][Full Text] [Related]
39. First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient.
Pollack SM; Lu H; Gnjatic S; Somaiah N; O'Malley RB; Jones RL; Hsu FJ; Ter Meulen J
J Immunother; 2017 Oct; 40(8):302-306. PubMed ID: 28891906
[TBL] [Abstract][Full Text] [Related]
40. Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas.
Lagarde P; Przybyl J; Brulard C; Pérot G; Pierron G; Delattre O; Sciot R; Wozniak A; Schöffski P; Terrier P; Neuville A; Coindre JM; Italiano A; Orbach D; Debiec-Rychter M; Chibon F
J Clin Oncol; 2013 Feb; 31(5):608-15. PubMed ID: 23319690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
